Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
Search or
𝛼
SK
SIGN UP
SIGN IN
bullish
United States Health Care
Biopharma Week in Review - Jul 8, 2024
Thematic (Sector/Industry)
316 Views
08 Jul 2024 22:03
Issuer-paid
The cost of Kisunla is $32K/year, which is at a premium to Leqembi (Biogen, Inc. [BIIB]/Eisai Co., Ltd. [ESAIY]) at $26.5K/year, but total cost per patient should be lower for Kisunla
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 7-minute read)
Related Insights
More »
Biogen’s Alzheimer’s Breakthroughs: Could AHEAD 3-45 Redefine Early Treatment?
Biogen Inc.: The Game-Changing Subcutaneous LEQEMBI Might Just Be Its Single-Biggest Future Growth Catalyst!
Biogen, Inc: Catalysts for Accelerating Leqembi Demand Growth
Biogen, Inc. - Steady as She Goes as the Ship Continues to Turn Slowly
Biogen, Inc: Breakthrough Drug Developer in Reset Mode; Initiating Coverage
Trending Collections
More »
Index Rebalance
Japan
Event-Driven
Equity Bottom-Up
India
Unpaywalled Equity-Bottom-Up
Philippines
Unpaywalled Insights
Japan Activism
China
Trending Insights
More »
HSBC (5 HK)'s Fair Offer for Hang Seng (11 HK)'s Minorities
[Japan Activism] Sun Corp (6736) Gets ANOTHER Public Activist - ValueAct Reports 7.9%
Vietnam: Global Index Inclusion & Passive Flows
Soft99 Corp (4464 JP): Potential Outcomes as the Board Responds to Effissimo Allegations
[Japan Event] Sony Financial (8729 JP) Moves On From ToSTNeT-3 Buybacks, Now In the Market
Top Unpaywalled Insights
More »
Beyond The Blue Chips: A Look At SGX’s iEdge Singapore Next 50
Aaron Brown: Quantitative Risk, Crypto, and the "Wrong Number" Revolution | New Barbarians Podcast
Beyond the Current Account Deficit: What Drives the US Dollar?
Curator's Cut: BABA Hedges, Substantive Spin-Offs & Japanese Activist Situations
Overview #36 - AI Hype, Mineral Might, and the Nuclear Revival
Discussions
(Paid Plans Only)
Insight Stream
Biopharma Week in Review - Jul 8, 2024
08 Jul 2024
Top
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.58.5
x